Haw Par Corporation Limited (HAWPY)
USD 28.64
(0.0%)
USD 28.64
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.98 SGD | 46.27% |
| 2022 | 0.67 SGD | 34.0% |
| 2021 | 0.50 SGD | -7.41% |
| 2020 | 0.54 SGD | -34.15% |
| 2019 | 0.82 SGD | -74.77% |
| 2018 | 3.25 SGD | 42.54% |
| 2017 | 2.28 SGD | 0.0% |
| 2016 | 2.28 SGD | -31.94% |
| 2015 | 3.35 SGD | 54.38% |
| 2014 | 2.17 SGD | 9.6% |
| 2013 | 1.98 SGD | -10.0% |
| 2012 | 2.20 SGD | 49.66% |
| 2011 | 1.47 SGD | -28.99% |
| 2010 | 2.07 SGD | 97.14% |
| 2009 | 1.05 SGD | -27.08% |
| 2008 | 1.44 SGD | -49.12% |
| 2007 | 2.83 SGD | 50.53% |
| 2006 | 1.88 SGD | 32.39% |
| 2005 | 1.42 SGD | 8.4% |
| 2004 | 1.31 SGD | 47.19% |
| 2003 | 0.89 SGD | 178.13% |
| 2002 | 0.32 SGD | -44.83% |
| 2001 | 0.58 SGD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.28 SGD | 12.0% |
| 2024 Q2 | 0.28 SGD | 0.0% |
| 2023 Q1 | 0.24 SGD | 50.0% |
| 2023 Q4 | 0.25 SGD | 0.0% |
| 2023 FY | - SGD | 46.27% |
| 2023 Q2 | 0.24 SGD | 0.0% |
| 2023 Q3 | 0.25 SGD | 4.17% |
| 2022 Q4 | 0.16 SGD | 0.0% |
| 2022 FY | - SGD | 34.0% |
| 2022 Q1 | 0.17 SGD | -34.62% |
| 2022 Q2 | 0.35 SGD | 105.88% |
| 2022 Q3 | 0.16 SGD | -54.29% |
| 2021 Q1 | 0.12 SGD | -7.69% |
| 2021 Q4 | 0.26 SGD | 100.0% |
| 2021 Q3 | 0.13 SGD | -45.83% |
| 2021 Q2 | 0.24 SGD | 100.0% |
| 2021 FY | - SGD | -7.41% |
| 2020 Q1 | 0.21 SGD | -8.7% |
| 2020 Q3 | 0.07 SGD | -84.1% |
| 2020 FY | - SGD | -34.15% |
| 2020 Q4 | 0.13 SGD | 99.39% |
| 2020 Q2 | 0.41 SGD | 95.24% |
| 2019 FY | - SGD | -74.77% |
| 2019 Q4 | 0.23 SGD | -77.67% |
| 2019 Q3 | 1.03 SGD | -37.2% |
| 2019 Q2 | 1.64 SGD | 310.0% |
| 2019 Q1 | 0.40 SGD | 8.11% |
| 2018 Q1 | 0.35 SGD | 34.62% |
| 2018 Q4 | 0.37 SGD | -64.42% |
| 2018 Q3 | 1.04 SGD | -30.2% |
| 2018 Q2 | 1.49 SGD | 325.71% |
| 2018 FY | - SGD | 42.54% |
| 2017 FY | - SGD | 0.0% |
| 2017 Q4 | 0.26 SGD | -64.38% |
| 2017 Q3 | 0.73 SGD | -22.34% |
| 2017 Q2 | 0.94 SGD | 213.33% |
| 2017 Q1 | 0.30 SGD | -16.67% |
| 2016 Q4 | 0.36 SGD | -53.25% |
| 2016 FY | - SGD | -31.94% |
| 2016 Q3 | 0.77 SGD | -12.5% |
| 2016 Q2 | 0.88 SGD | 238.46% |
| 2016 Q1 | 0.26 SGD | -25.71% |
| 2015 FY | - SGD | 54.38% |
| 2015 Q4 | 0.35 SGD | -45.31% |
| 2015 Q3 | 0.64 SGD | -69.81% |
| 2015 Q2 | 2.12 SGD | 783.33% |
| 2015 Q1 | 0.24 SGD | -29.41% |
| 2014 Q3 | 0.49 SGD | -56.64% |
| 2014 Q4 | 0.34 SGD | -30.61% |
| 2014 Q1 | 0.22 SGD | -50.0% |
| 2014 FY | - SGD | 9.6% |
| 2014 Q2 | 1.13 SGD | 413.64% |
| 2013 Q1 | 0.14 SGD | -78.13% |
| 2013 Q3 | 0.41 SGD | -58.59% |
| 2013 Q2 | 0.99 SGD | 607.14% |
| 2013 FY | - SGD | -10.0% |
| 2013 Q4 | 0.44 SGD | 7.32% |
| 2012 Q1 | 0.13 SGD | -50.0% |
| 2012 Q3 | 0.38 SGD | -53.66% |
| 2012 Q4 | 0.64 SGD | 68.42% |
| 2012 FY | - SGD | 49.66% |
| 2012 Q2 | 0.82 SGD | 530.77% |
| 2011 Q4 | 0.26 SGD | 85.71% |
| 2011 Q1 | 0.12 SGD | -76.47% |
| 2011 Q2 | 0.95 SGD | 691.67% |
| 2011 FY | - SGD | -28.99% |
| 2011 Q3 | 0.14 SGD | -85.26% |
| 2010 Q2 | 0.88 SGD | 576.92% |
| 2010 Q4 | 0.51 SGD | -7.27% |
| 2010 FY | - SGD | 97.14% |
| 2010 Q3 | 0.55 SGD | -37.5% |
| 2010 Q1 | 0.13 SGD | 141.94% |
| 2009 Q1 | 0.17 SGD | 0.0% |
| 2009 Q4 | -0.31 SGD | -175.61% |
| 2009 Q3 | 0.41 SGD | -48.1% |
| 2009 Q2 | 0.79 SGD | 364.71% |
| 2009 FY | - SGD | -27.08% |
| 2008 FY | - SGD | -49.12% |
| 2007 FY | - SGD | 50.53% |
| 2006 FY | - SGD | 32.39% |
| 2005 FY | - SGD | 8.4% |
| 2004 FY | - SGD | 47.19% |
| 2003 FY | - SGD | 178.13% |
| 2002 FY | - SGD | -44.83% |
| 2002 Q2 | 0.10 SGD | 0.0% |
| 2002 Q4 | -0.04 SGD | 0.0% |
| 2001 FY | - SGD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | 74.479% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | 74.742% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | -1300.0% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 112.189% |
| Novartis AG | 7.63 USD | 87.156% |
| PT Kalbe Farma Tbk. | 0.00 USD | -25028.205% |